FDA Lifts Clinical Hold for Expanded Access Program Protocol

On December 20, 2019, the U.S. Food and Drug Administration (FDA) lifted the clinical hold on MAPS’ proposed Expanded Access protocol for MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD).